Downstream processing of oncoretroviral and lentiviral gene therapy vectors.
Retroviral vectors from both oncoretroviral and lentiviral origins have a great potential as gene delivery vehicles. A number of research groups have devoted considerable effort to the development of large-scale production strategies for retroviral vectors. However, the manufacturing of clinical-grade vectors for gene therapy, especially for in vivo applications, additionally requires scaleable purification strategies to remove the contaminants present in the harvested supernatants while preserving the functionality of the vectors. In this article, we review recent advances made in the field of downstream processing of retroviral vectors. The methods currently described in the literature for clarification, concentration and purification of retroviral vectors will be presented, with special emphasis on novel chromatography methods that open up the possibility to selectively and efficiently purify retroviruses on a large-scale. Problems associated with stability and quantification of retroviral particles will be outlined and future challenges will be discussed.
Segura
María de Las Mercedes
MM
Department of Chemical Engineering, Centre de Recherche sur la fonction, la structure et l'ingénierie des protéines, Université Laval, Québec, Canada G1K 7P4.
Kamen
Amine
A
Garnier
Alain
A
D004279:DNA, Viral / Q000032:analysis / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D016086:Lentivirus / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification*; D009858:Oncogenic Viruses / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification*
D004279:DNA, Viral